HUM Humana, Inc.
Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty, Healthcare Services, and Individual Commercial. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance benefits. The Healthcare Services segment offer services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics services to other Humana businesses, as well as external health plan members, external health plans, and other employers.. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand. The company was founded by David A. Jones, Sr. and Wendell Cherry in 1961 and is headquartered in Louisville, KY.
Company profile
Ticker
HUM
Exchange
CEO
Bruce Dale Broussard
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Unitedhealth • Anthem • Cigna Holding • Cigna • Centene • WellCare Health Plans • Molina Healthcare • Trupanion ...
SEC CIK
Corporate docs
IRS number
610647538
HUM stock data
()
Calendar
31 Jul 19
17 Oct 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 16.25B | 16.11B | 14.17B | 14.21B | |
| Net income | 940M | 566M | 355M | 644M | |
| Diluted EPS | 6.94 | 4.16 | 2.58 | 4.65 | |
| Net profit margin | 5.79% | 3.51% | 2.51% | 4.53% | |
| Operating income | 1.12B | 847M | 517M | 961M | |
| Net change in cash | 901M | 1.53B | -1.8B | -3.91B | |
| Cash on hand | 4.78B | 3.88B | 2.34B | 4.14B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 56.91B | 53.77B | 54.38B | 54.29B | |
| Net income | 1.68B | 2.45B | 614M | 1.28B | |
| Diluted EPS | 12.16 | 16.81 | 4.07 | 8.44 | |
| Net profit margin | 2.96% | 4.55% | 1.13% | 2.35% | |
| Operating income | 3.1B | 4.26B | 1.74B | 2.35B | |
| Net change in cash | -1.7B | 165M | 1.31B | 636M | |
| Cash on hand | 2.34B | 4.04B | 3.88B | 2.57B |
Financial data from Humana earnings reports
Financial report summary
?Competition
Cigna Holding • Caremark Ulysses Holding • Unitedhealth • ABIOMED • Health Net • Pacificare Health Systems • Medco Health Solutions • Healthspring • DCP Holding • Champion Pain CareManagement Discussion
- agreement will be determined based on a volume-weighted average price of our common stock during the purchase period.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
AIP, analyzing, criteria, Dollar, embedded, Inline, instance, institution, iXBRL, Maker, MayYet, Plansor, PubliclyAnnounced, PurchasedUnder, pursued, repayment, replaced, satisfaction, smaller, thousand, unused
Removed:
April, EGWP, healthier, Letter, percent, reinvested, retirement, sector, treatment, typical, Waiver
Financial reports
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
1 Aug 18
10-Q
2018 Q1
Quarterly report
2 May 18
10-K
2017 FY
Annual report
16 Feb 18
10-Q
2017 Q3
Quarterly report
8 Nov 17
10-Q
2017 Q2
Quarterly report
2 Aug 17
10-Q
2017 Q1
Quarterly report
3 May 17
Current reports
8-K
Departure of Directors or Certain Officers
15 Oct 19
8-K
Humana Elects Karen W. Katz to Board of Directors
23 Sep 19
8-K
Regulation FD Disclosure
3 Sep 19
8-K
Entry into a Material Definitive Agreement
15 Aug 19
8-K
Humana Prices $1.0 Billion Debt Offering
9 Aug 19
8-K
Entry into a Material Definitive Agreement
2 Aug 19
8-K
Results of Operations and Financial Condition
31 Jul 19
8-K
Departure of Directors or Certain Officers
19 Jul 19
8-K
Regulation FD Disclosure
3 Jun 19
8-K
Regulation FD Disclosure
31 May 19
Registration and prospectus
424B5
Prospectus supplement for primary offering
9 Aug 19
FWP
Free writing prospectus
8 Aug 19
424B5
Prospectus supplement for primary offering
8 Aug 19
S-8
Registration of securities for employees
1 May 19
S-3ASR
Automatic shelf registration
9 Mar 18
424B5
Prospectus supplement for primary offering
18 Dec 17
424B5
Prospectus supplement for primary offering
14 Dec 17
FWP
Free writing prospectus
14 Dec 17
424B2
Prospectus for primary offering
15 Mar 17
424B5
Prospectus supplement for primary offering
13 Mar 17
Proxies
DEFA14A
Additional proxy soliciting materials
8 Apr 19
DEFA14A
Additional proxy soliciting materials
6 Mar 19
DEF 14A
Definitive proxy
6 Mar 19
DEFA14A
Additional proxy soliciting materials
2 Apr 18
DEF 14A
Definitive proxy
7 Mar 18
DEFA14A
Additional proxy soliciting materials
7 Mar 18
PX14A6G
Letter to shareholders
27 Mar 17
DEF 14A
Definitive proxy
8 Mar 17
DEFA14A
Additional proxy soliciting materials
8 Mar 17
DEF 14A
Definitive proxy
9 Mar 16
Other
CT ORDER
Confidential treatment order
10 Feb 14
UPLOAD
Letter from SEC
11 Jun 12
CORRESP
Correspondence with SEC
9 May 12
UPLOAD
Letter from SEC
26 Apr 12
CT ORDER
Confidential treatment order
6 Mar 12
UPLOAD
Letter from SEC
5 May 11
CORRESP
Correspondence with SEC
7 Apr 11
UPLOAD
Letter from SEC
24 Mar 11
CT ORDER
Confidential treatment order
15 Mar 11
UPLOAD
Letter from SEC
15 Sep 10